New drug combo targets Hard-to-Treat cancers in early trial
Disease control
Completed
This early-phase study tested a new drug called ADG116, alone or with other drugs, in 72 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find safe doses and understand side effects. The study is now complete, and result…
Phase: PHASE1 • Sponsor: Adagene Inc • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC